The Food and Drug Administration today revoked the emergency use authorization that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, FDA said that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks for its authorized use. For more details, see the FDA news release.

Related News Articles

Headline
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee today by a unanimous vote recommended that the FDA issue an…
Headline
The AHA has received a $1 million grant from the Centers for Disease Control and Prevention to continue for one year its efforts to encourage COVID-19…
Headline
The Food and Drug Administration yesterday released an updated enforcement policy related to face masks, barrier face coverings, face shields,…
Blog
Post-acute care (PAC) providers continue to play a central role in COVID-19 response and recovery. In particular, providers in COVID-19 hotspots have been…
Headline
The Centers for Disease Control and Prevention Friday updated its guidance for health care personnel on preventing and controlling infections during the COVID-…
Headline
As strongly advocated by the AHA, the Centers for Medicare & Medicaid Services today announced that it is rescinding prior audit denials for hospitals that…